<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392830</url>
  </required_header>
  <id_info>
    <org_study_id>ALZ002-101</org_study_id>
    <nct_id>NCT04392830</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses (SAD-MAD) of ALZ002 DS in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allianz Pharmascience Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allianz Pharmascience Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
      single-ascending and multiple-ascending doses of ALZ002 DS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of SAEs and treatment-related adverse events</measure>
    <time_frame>Baseline through Study Completion (up to Day 14)</time_frame>
    <description>Incidence of SAEs and treatment-related severe AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) will be assessed</measure>
    <time_frame>predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose; Day 3: predose; Day 4:predose; Day 5:predose; Day 6: predose; Day7: predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose</time_frame>
    <description>Maximum observed plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) will be assessed</measure>
    <time_frame>predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose; Day 3: predose; Day 4:predose; Day 5:predose; Day 6: predose; Day7: predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma MicroRNA (miRNA) concentration will be measured</measure>
    <time_frame>predose; Day 2: predose; Day 4:predose; Day7: predose; Day 14</time_frame>
    <description>Plasma miRNA concentration versus time curve</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ALZ002 DS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAD: 6 cohorts of subjects are planned to be orally dosed, ranging from 15 mg - 800 mg.
MAD: 3 cohorts of subjects are planned to be orally dosed once daily for 7 consecutive days, ranging from 300 mg - 800 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALZ002 DS</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>ALZ002 DS</arm_group_label>
    <other_name>JM17</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or non-childbearing potential female subjects, non-smoker (no use of
             tobacco or nicotine products within 3 months prior to screening), ≥18 and ≤55 years of
             age at screening.

          -  Body mass index &gt; 18.5 and &lt; 30.0 kg/m2, and body weight ≥ 50.0 kg for males and ≥
             45.0 kg for females at screening visit.

          -  Capable of consent.

        Exclusion Criteria:

          -  Any clinically significant abnormality or abnormal laboratory test results

          -  Positive urine drug screen, alcohol breath test, or urine cotinine test

          -  History of significant allergic reactions to any drug.

          -  Participation in a clinical research study involving the administration of an
             investigational or marketed drug or device

          -  History of clinically significant opportunistic infection

          -  Presence of fever (body temperature &gt; 38°C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Manager</last_name>
    <phone>+886-2-2700-5818</phone>
    <email>yi-ju.hsieh@allianzpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cmax clinical research</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
      <phone>+61 8 7088 7939</phone>
      <email>Dianne.pepper@cmax.com.au</email>
    </contact>
    <investigator>
      <last_name>Nicholas Farinola, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 10, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

